DK0573605T3 - Fremstilling af faktor IX - Google Patents

Fremstilling af faktor IX

Info

Publication number
DK0573605T3
DK0573605T3 DK92908513T DK92908513T DK0573605T3 DK 0573605 T3 DK0573605 T3 DK 0573605T3 DK 92908513 T DK92908513 T DK 92908513T DK 92908513 T DK92908513 T DK 92908513T DK 0573605 T3 DK0573605 T3 DK 0573605T3
Authority
DK
Denmark
Prior art keywords
factor
contained
preparations
disclosed
derived
Prior art date
Application number
DK92908513T
Other languages
Danish (da)
English (en)
Inventor
Chin C Huang
Takashi Enkoji
Laura Ho
Richard R Kleszynski
Richard L Weeks
Fred Feldman
Original Assignee
Rhone Poulenc Rorer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Int filed Critical Rhone Poulenc Rorer Int
Application granted granted Critical
Publication of DK0573605T3 publication Critical patent/DK0573605T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
DK92908513T 1991-03-01 1992-02-26 Fremstilling af faktor IX DK0573605T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292791A 1991-03-01 1991-03-01
PCT/US1992/001600 WO1992015324A1 (en) 1991-03-01 1992-02-26 Preparation of factor ix

Publications (1)

Publication Number Publication Date
DK0573605T3 true DK0573605T3 (da) 2001-01-02

Family

ID=24659784

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92908513T DK0573605T3 (da) 1991-03-01 1992-02-26 Fremstilling af faktor IX

Country Status (17)

Country Link
US (3) US6063909A (fi)
EP (1) EP0573605B1 (fi)
JP (1) JP3418621B2 (fi)
AT (1) ATE195877T1 (fi)
AU (1) AU671586B2 (fi)
BR (1) BR9205700A (fi)
CA (1) CA2105282C (fi)
DE (1) DE69231401T2 (fi)
DK (1) DK0573605T3 (fi)
ES (1) ES2150914T3 (fi)
FI (1) FI114969B (fi)
GR (1) GR3034946T3 (fi)
MX (1) MX9200882A (fi)
NO (1) NO315856B1 (fi)
RU (1) RU2142806C1 (fi)
SG (1) SG48282A1 (fi)
WO (1) WO1992015324A1 (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2150914T3 (es) * 1991-03-01 2000-12-16 Rhone Poulenc Rorer Int Preparacion de factor ix.
JP3735112B2 (ja) * 1992-08-27 2006-01-18 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 凝血性蛋白質に特異的な抗体、未変性蛋白質を単離するためのそれらの利用、その蛋白質の蛋白質分解性開裂産物を含まない凝血性組成物
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
ES2154059T3 (es) * 1996-10-31 2001-03-16 Roche Diagnostics Gmbh Metodo para la determinacion de la actividad catalitica del factor ixa.
US7125841B2 (en) * 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
CA2520970A1 (en) * 2003-04-09 2004-10-28 Robert G. Schaub Hemophilia treatment by inhalation of coagulation factors
US8012498B2 (en) 2004-07-12 2011-09-06 Sandhya Goyal Topical gel formulation comprising organophosphate insecticide and preparation thereof
US8158139B2 (en) * 2004-07-12 2012-04-17 Taro Pharmaceuticals North America, Inc. Topical gel formulation comprising organophosphate insecticide and preparation thereof
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
JP6250931B2 (ja) 2010-01-18 2017-12-20 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 血液凝固因子の精製
DK2553095T3 (en) * 2010-03-30 2017-01-23 Octapharma Ag PROCEDURE FOR CLEANING VITAMIN K-DEPENDENT PROTEINS SUCH AS COAGULATION FACTOR IX
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
DE3101752A1 (de) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
DE3485711D1 (de) * 1983-03-04 1992-06-17 Scripps Clinic Res Immunoadsorbens und verfahren zur zurueckgewinnung von vitamin-k-abhaengigen proteinen mittels dieses adsorbens.
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
ATE36457T1 (de) * 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
JPS60132912A (ja) * 1983-12-21 1985-07-16 Kao Corp シヤンプ−組成物
ATE74164T1 (de) * 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
FR2600334B1 (fr) 1986-06-23 1989-05-12 Transgene Sa Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
EP0317376B2 (fr) 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
JPH01258700A (ja) 1988-04-05 1989-10-16 Green Cross Corp:The 血液凝固第４因子の精製方法
DE3826792C1 (fi) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DE3914869C1 (fi) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
AT402261B (de) * 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
ES2150914T3 (es) * 1991-03-01 2000-12-16 Rhone Poulenc Rorer Int Preparacion de factor ix.

Also Published As

Publication number Publication date
FI933814A (fi) 1993-09-01
AU671586B2 (en) 1996-09-05
AU1642992A (en) 1992-10-06
NO315856B1 (no) 2003-11-03
CA2105282A1 (en) 1992-09-02
US6063909A (en) 2000-05-16
ATE195877T1 (de) 2000-09-15
JP3418621B2 (ja) 2003-06-23
EP0573605B1 (en) 2000-08-30
FI114969B (fi) 2005-02-15
DE69231401D1 (de) 2000-10-05
SG48282A1 (en) 1998-04-17
JPH06505494A (ja) 1994-06-23
FI933814A0 (fi) 1993-09-01
US6280729B1 (en) 2001-08-28
CA2105282C (en) 2002-09-24
DE69231401T2 (de) 2001-02-08
US6043215A (en) 2000-03-28
ES2150914T3 (es) 2000-12-16
EP0573605A4 (en) 1994-11-23
WO1992015324A1 (en) 1992-09-17
NO933114D0 (no) 1993-09-01
RU2142806C1 (ru) 1999-12-20
NO933114L (no) 1993-09-01
MX9200882A (es) 1992-09-01
BR9205700A (pt) 1994-06-28
GR3034946T3 (en) 2001-02-28
EP0573605A1 (en) 1993-12-15

Similar Documents

Publication Publication Date Title
DK0573605T3 (da) Fremstilling af faktor IX
NO308587B1 (no) FremgangsmÕte for fremstilling av en konsentrert fibrinogen- oppløsning og anvendelse derav
DK0397420T3 (da) Enzymatisk fjernelse af en aminoterminal proteinsekvens
DK0410207T3 (da) Stabilisering af højrensede proteiner.
ATE65185T1 (de) Thrombolytische zusammensetzung und verfahren zu deren herstellung.
ZA200005696B (en) Stable concentrated rare earth carboxylate liquids.
RU93053992A (ru) Способ очистки и хранения фактора ix, водный раствор очищенного фактора ix, композиция, содержащая фактор ix, способ лечения
NO2006006I1 (no) Aktivert protein C
DE69016087D1 (de) Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung.
SE8704832L (en) Prepn. for dissolving caries - comprises nitrogen-contg. cpds. and sodium hypochlorite
ATE94168T1 (de) Peptide.
DE3855751D1 (en) Hypoglycemische peptide
DE3650564T2 (de) Dipeptide-Analoge von Aspertam und Verfahren zur deren Herstellung, sowie eine neue Herstellung von Aspertam
SE9502927D0 (sv) Solution containing IGF-I
DE68905796T2 (de) Chromoglycinsaeure-natriumsalz enthaltende aerosolzubereitungen.
DE69517247D1 (de) Phosphorylierte Derivate von Verbindungen mit antiinflammatorischen oder analgetischer Wirkung
ES2067140T3 (es) Compuestos fenilester de acido benzoico y composiciones inhibidoras de la elastasa que contienen los mismos.
CO4790097A1 (es) Farmacos